Miglustat. Oxford GlycoSciences/Actelion.
Copyright policy )Miglustat. Oxford GlycoSciences/Actelion.
Oxford GlycoSciences and Actelion have developed and launched miglustat (OGT-918; Vevesca; Zavesca) for the treatment of type 1 Gaucher disease. Miglustat is an orally administered small-molecule glucosylceramide glucosyltransferase inhibitor licensed from Searle, and it is also in development for the treatment of other glycolipid storage disorders such as Tay-Sachs, Fabry and Niemann-Pick type C diseases. In November 2002, miglustat received EU approval for the treatment of Gaucher disease and was launched in the UK in March 2003 by Actelion. At this time, additional EU launches were expected over the next few months.
- Addenbrooke's Hospital United Kingdom
- University of Cambridge United Kingdom
- Cambridge University Hospitals NHS Foundation Trust United Kingdom
Niemann-Pick Diseases, Gaucher Disease, Clinical Trials, Phase I as Topic, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Animals, Fabry Disease, Glucosylceramidase, Humans, Carbohydrate Metabolism, Inborn Errors
Niemann-Pick Diseases, Gaucher Disease, Clinical Trials, Phase I as Topic, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Animals, Fabry Disease, Glucosylceramidase, Humans, Carbohydrate Metabolism, Inborn Errors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).46 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!